Blue Earth Therapeutics is highlighting results for its radiohybrid lutetium labelled, prostate specific membrane antigen (PSMA)-targeted, investigational radioligand therapy.
Radiation dosimetry and pharmacokinetic data from the 13 metastatic castrate-resistant prostate cancer patients enrolled in the phase I portion of a phase I/II clinical trial of the Lutetium-177 (Lu-177) rhPSMA-10.1 Injection showed proportionately higher absorbed radiation doses in tumors than in healthy tissues.
The data shows that the injection has high ratios for absorbed radiation dose to tumors versus dosage to healthy tissues, with a measured average tumor-to-salivary gland ratio of 73 and tumor-to-kidney ratio of 32. The median absorbed radiation dose to tumors defined by SPECT imaging was 8.9 Gy for each GBq of administered radioactivity. The average absorbed radiation dose to the kidneys was 0.27 Gy/GBq; to salivary glands, 0.13 Gy/GBq.
The average biological half-life in tumors for the injection was 338 hours. When paired with the 6.7-day physical half-life of Lu-177, this gave an effective mean half-life of 91.4 hours.
Phase II of the trial will focus on administering higher overall injected radioactivity in comparison to recent similar phase III trials, front loading of administered radioactivity in early cycles, and extending the duration of radioactivity administration beyond 36 weeks.
Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.